MUC16 and plasma cell myeloma: PSMA and MUC16 were selected to represent targets of solid tumor malignancies, while CD20 and BCMA (B-cell maturation antigen) were selected for targets of hematologic malignancies (i.e. B-cell lymphoma and multiple myeloma, respectively)12–16.